Q-omics provides the consensus-scored GCOM2 profile across patient tissues and cancer cell-line models. GCOM2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, GCOM2 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, GCOM2 RNA expression shows 16,459 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, and UVM as cancer lineages where GCOM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCOM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCOM2 survival associations across molecular data types. GCOM2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCOM2 RNA expression–survival associations across cancer types. High GCOM2 expression shows unfavorable associations in KIRC and UVM, but favorable associations in LUSC, CESC, LIHC and UCS. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for GCOM2 RNA expression.
This table summarizes GCOM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GCOM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCOM2 shows lower tumor expression in UCEC and HNSC and higher tumor expression in LUSC, LIHC, CHOL and KIRC. The LUSC box plot shows higher GCOM2 RNA expression in tumor versus normal tissue (log2 FC = +0.444, t-test p < 0.001).
This table shows molecular features associated with GCOM2 in patient tissues and cancer cell lines. In patient samples, GCOM2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
